Process for attenuated varicella zoster virus vaccine production
First Claim
Patent Images
1. A composition useful for growing cells in monolayer culture, the composition consisting essentially of SFRE-2 medium supplemented with between 0.2 mg/mL and 0.4 mg/mL soybean lipid, and the cells being selected from MRC-5 cells, WI-38 cells and Vero cells.
4 Assignments
0 Petitions
Accused Products
Abstract
A live, attenuated varicella zoster virus vaccine is produced with enhanced yield of VZV. The new process makes mass production of a live VZV vaccine more practical. In addition, optimized monoloyer cell culture conditions provide a process for maximizing monolayer cell density which is useful for enhancing viral vaccine production. According to this process, cell densities approaching 500,000 cells/cm2 are routinely achieved in conventional culture vessels.
35 Citations
1 Claim
-
1. A composition useful for growing cells in monolayer culture, the composition consisting essentially of SFRE-2 medium supplemented with between 0.2 mg/mL and 0.4 mg/mL soybean lipid, and the cells being selected from MRC-5 cells, WI-38 cells and Vero cells.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeMerck Sharp & Dohme Corporation (Merck & Co., Inc.)
-
Original AssigneeMerck & Co., Inc.
-
InventorsKrah, David L., Friedman, Paul A., Provost, Philip J.
-
Primary Examiner(s)Smith, Lynette F.
-
Application NumberUS08/347,345Time in Patent Office820 DaysField of Search424/230.1, 435/240.21, 435/235.1, 435/240.1US Class Current435/404CPC Class CodesA61K 2039/5254 avirulent or attenuatedA61K 39/12 Viral antigensA61K 39/25 Varicella-zoster virusA61P 31/12 AntiviralsA61P 31/22 for herpes virusesC12N 2500/36 LipidsC12N 2710/16734 Use of virus or viral compo...C12N 5/0018 Culture media for cell or t...Y02A 50/30 Against vector-borne diseas...
